MABTAS RA 500MG

DESCRIPTION

Mabtas RA 500mg is an anticancer medicine which prevents the growth and spread of
cancer cells in the body. Mabtas RA 500mg injection also indicated for the treatment
of Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with
another anticancer drugs like methotrexate is used for rheumatoid arthritis symptoms
in adult treatment. Mabtas RA 500mg with steroid regimen combination is given for
the treatment of some rare disorders which cause blood vessels and other tissues
inflammation in the body.

INDICATION

Mabtas RA 500mg and hyaluronidase human injection are given alone or combination
with other drugs to treat certain types of non-Hodgkin's lymphoma and chronic
lymphocytic leukemia (cancer start in WBC).
Mabtas RA 500mg injection is also used with methotrexate (Otrexup, Rasuvo,
Xatmep, others) for the treatment rheumatoid arthritis symptoms in adults that have
been already treated with some type of regimenknown as tumor necrosis factor (TNF)
inhibitor.
Mabtas RA 500mg is a type in a classification of drugs called monoclonal antibodies.
Mabtas RA 500mg injection is used to killing cancer cells to treat NHL,CLL,
rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis
by stopping the activity of the part of the immune system that will damage the joints,
veins, and other blood vessels and cause damage to organs (heart and lungs).

MECHANISM OF ACTION

Mabtas RA 500mg is a type of class called as monoclonal antibody and which is a

new type of "targeted" cancer treatment and an integral part of the body's immune
system. Naturally the body build antibodies in along with to an antigen which has
entered the body and attach to the antigen for destruction by the immune system.
An essential cells only aimed by monoclonal antibiotics, they may leads to less
toxicity to healthy cell and it is usually treatment recommended only for cancers in
which antigens (and the respective antibodies) have been already identified.
Mabtas RA 500mg injection works by linking to the CD20 antigen on normal and
malignant B-cells. Hence the body's essential immune security is initiated to attack
and kill the marked B-cells. Stem cells i.eyoung cells in the bone marrow which will
grow into the various cell types and do not have the CD20 antigen. After treatment,
CD20 antigen allows healthy B-cells to multiply
PRODUCT DETAILS

Brand : Mabtas RA
Ingredients : Rituximab
Strength : 500mg
Manufactured : Intas pharmaceuticals ltd
Package : injection

Mabtas ra 500mg

PHARMACOKINETICS

ABSORPTION

Not available

DISTRIBUTION

volume of distribution is 3.1 L

METABOLISM

Mabtas RA 500mg metabolized by human antimurine antibody production.

EXCRETION

not available
The half-life of NHL is 22 days and for RA is 18.0 days, GPA and microscopic
polyangiitis is 23 days

DOSAGE MANAGEMENT

Mabtas RA 500mg injection is recommended to administer only through intravenous

infusion not by IV push or bolus.

BEFORE EACH INFUSION PREMEDICATE

First infusion: initially rate of 50 mg/hr. is given, in not showing infusion toxicity, rate
raised up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
Successive infusion: 100 mg/hr.-initiatedrate, in not showing infusion toxicity, rate
raised up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
Premedication with corticosteroids must be considered, if Mabtas RA
500mg combination with CHOP chemotherapy is not given.

LOW GRADE OR FOLLICULAR NON-HODGKINS LYMPHOMA

Dose is 375 mg/m2 as an IV infusion.

Once weeksfor 4 or 8 doses administrated for Relapsed treatment
Relapsed Retreatment for once weekly for 4 doses administrated.
Untreated Previously: given on day 1 of each cycle of chemotherapy, up to 8 doses. In
complete or partial response of patient, start with 8 weeks for maintenance following
Mabtas RA in combination with chemotherapy completed then administer 8weeks for
12 doses as a single agent.
Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non –
progression (following CVP chemotherapy completion 6 – 8 cycles)
On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse large B- cell NHL.

CHRONIC LYMPHOCYTIC LEUKEMIA

Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500

mg/m2 on day 1 of 2-6 cycles every 28 days.

COMPONENT OF ZEVALIN FOR TREATMENT OF NHL

Prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-)

Zevalin administer Mabtas RA infusion about 250 mg/m2 within 4 hours
Before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin 7–9
days.
RHEUMATOID ARTHRITIS

Mabtas RA 500mg is administer with methotrexate combination

Mabtas RA 500mg injection administrating as two doses of 100mg IV infusion 2
weeks separated.
When glucocorticoids administered as methyl prednisolone 100mg IV
Subsequent course based on clinical evaluation should administer every 24 weeks, but
not early than every 16 weeks.

GRANULOMATOSIS POLYANGITIS AND MICROSCOPIC POLYANGITIS

Weekly once for 4 weeks administer Dose of 375 mg/m2 IV infusion

While Glucocorticoids combination with methylprednisolone by dose of 1000 mg IV/
day given for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended
for the treatment of symptoms of seriousvasculitis . This drug should initiate within 14
days before or with the starting of Mabtas RA and may continue during and after the
4-week course with treatment of Mabtas RA 500mg drug.
Safety and not established for subsequent infusion.

ADMINISTRTION

Take an Mabtas RA 500mg injection amount and diluted to final concentration of 1

mg/ml up to 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in
water). Invert gently the bag and mix the solution. Dispose unused drug left in vial.

Chronic lymphocytic leukemia

PRECAUTIONS

Allergic condition against Mabtas RA 500mg or any other medication informs your
doctor.
Concerning your history of drug used which include in prescription, non-prescription,
vitamins &supplements, nutritional products just inform the doctor.
While using Mabtas RA 500mg injection do not take any vaccination or immunization
without taking advice from doctors.
Avoid use of Mabtas RA 500mg if you are pregnant. It will harm the baby unborn,
while using Mabtas RA 500mg injection use correct birth control to prevent
pregnancy and for at least 2 weeks after your treatment ends. Mabtas RA 500mg may
affect the ability to have children in women. Inform your doctor if you planning to
pregnant.
It is unknown whether Mabtas RA 500mg injection passes into breast milk, avoid
breast-feed while on Mabtas RA 500mg treatment.

SIDE EFFECTS

Common effects:
fever and chills (flu like symptoms)
Less common side effects:
Weakness; nausea; headache; cough; dyspnea; pharyngitis

DRUG INTERACTION

Mabtas RA 500mg injection drug interaction has limited data is available at present.
Combination with fludarabine or cyclophosphamide has no effects in
pharmacokinetics in CLL patients.
Combination with methotrexate had no effects in pharmacokinetics.

CONTRAINDICATIONS

Hypersensitivity or murine proteins.

Active severe infections in rheumatoid arthritis
Uncontrolled cardiac disease.

PREGNANCY

Category C: animal studies reproduction shown an adverse effect on the fetus. The
drug has no enoughand well controlled studies in humans, using in pregnant women
benefits by warrant use of the drug.
LACTATION

Mabtas RA 500mg excreted into human milk is unknown. Due to the drug belongs to
large protein molecule, no information is available. Women should not breast feed
during Mabtas RA 500mg treatment and 12 months following last dose.

STORAGE

• Store at 20°C – 30°C

• Use the drug before expiry date
• Protected from direct sunlight
• Do not freeze or shake.
• Keep away from the children’s
• Discard the unused drug by asking the advice from doctor or pharmacist.

MISSED DOSE

Mabtas RA 500mg injection excreted into human milk is unknown. Due to the drug
belongs to large protein molecule, no information is available. Women should not
breast feed during Mabtas RA 500mg treatment and 12 months following last dose.

OVERDOSAGE

If the patients had high dose of Mabtas RA 500mg then seek immediately to the
emergency department or poison control help line. Please consult the doctor for
further clarification.

CONTACT US

PHONE NO : +91-9940472902

EMAIL : millionhealthpharmaceuticals@gmail.com

WEBSITE URL : https://millionpharma.com/mabtas-ra-500mg.php

.